Phase 1 N=10 Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Uveal Melanoma · Choroid Neoplasm
Primary: Occurrence of Adverse Events — 1; 3; 5; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
Rosacea
Primary: Percent Change From Baseline in the Rosacea Clinical Score Card — -0.63; -0.00063; -0.65; -0.34 percent change
Phase 2 N=89 Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSS — -1.17; -0.69; -2.43; -1.65 units on a scale
Phase 2 N=606 Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSS — -3.57; -2.31; -2.96; -1.48 score on a scale
Early Phase 1 N=28 Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama
Toxic Effect of Other Corrosive Organic Compounds
Primary: Percent Change From Baseline for Total PCB Levels — 92; 96 % of baseline total PCBs
Phase 2 N=118 Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Previously Treated Metastatic Colorectal Cancer
Primary: Number of Participants Experiencing a Dose Limiting Toxicity — 1; 2; 1; 1 Participants
Phase 2 N=80 The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.
Cardiorenal Syndrome
Primary: Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values — 8; 5 Participants
Phase 2 N=58 A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
Acne Vulgaris
Primary: Maximum Plasma Concentration (Cmax) — 180.78; 529.91 pg/mL
Phase 2 N=47 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Maximum Tolerated Dose (MTD) of Gemcitabine — 500 mg/m^2
N/A N=99 Nasal Intubation Using King Vision Video Laryngoscopy
Nasal Intubation
Primary: Time to Intubation — 37.6; 35.4; 46.8 second
Phase 2 N=245 Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total Score — -1.18; -1.17 score on a scale
Phase 3 N=466 Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Relapsed Multiple Myeloma · Refractory Multiple Myeloma
Primary: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) — 68; 110; 86; 202 Participants — p=0.0014
N/A N=30 Investigating Accelerated Learning and Memory in Healthy Subjects Using a Face Name Memory Task
Healthy Adults
Primary: Associative Memory Assessed by a Face Name Associate Memory Experiment — 44.22; 35.44 Percent of Correct Name to Face Matches — p=<.049
Phase 2 N=104 Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief of Dentin Hypersensitivity
Dentin Hypersensitivity · Dentin Sensitivity
Primary: Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Baseline (Day 0) — 2.61; 2.60 Score on a scale
N/A N=72 Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatment of Myopia and Myopic Astigmatism.
Myopia · Astigmatism
Primary: Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or Better — 99.2 percentage of eyes